476 related articles for article (PubMed ID: 19047294)
1. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.
Büchner T; Berdel WE; Haferlach C; Haferlach T; Schnittger S; Müller-Tidow C; Braess J; Spiekermann K; Kienast J; Staib P; Grüneisen A; Kern W; Reichle A; Maschmeyer G; Aul C; Lengfelder E; Sauerland MC; Heinecke A; Wörmann B; Hiddemann W
J Clin Oncol; 2009 Jan; 27(1):61-9. PubMed ID: 19047294
[TBL] [Abstract][Full Text] [Related]
2. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
[TBL] [Abstract][Full Text] [Related]
3. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.
Scholl S; Theuer C; Scheble V; Kunert C; Heller A; Mügge LO; Fricke HJ; Höffken K; Wedding U
Eur J Haematol; 2008 Mar; 80(3):208-15. PubMed ID: 18081718
[TBL] [Abstract][Full Text] [Related]
4. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
[TBL] [Abstract][Full Text] [Related]
5. FLT3 mutations in normal karyotype acute myeloid leukemia in first complete remission treated with autologous peripheral blood stem cell transplantation.
Yoshimoto G; Nagafuji K; Miyamoto T; Kinukawa N; Takase K; Eto T; Kato K; Hayashi S; Kamimura T; Ohno Y; Taniguchi S; Harada M
Bone Marrow Transplant; 2005 Dec; 36(11):977-83. PubMed ID: 16184177
[TBL] [Abstract][Full Text] [Related]
6. Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia.
Colovic N; Tosic N; Aveic S; Djuric M; Milic N; Bumbasirevic V; Colovic M; Pavlovic S
Ann Hematol; 2007 Oct; 86(10):741-7. PubMed ID: 17579862
[TBL] [Abstract][Full Text] [Related]
7. Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia.
Rao AV; Valk PJ; Metzeler KH; Acharya CR; Tuchman SA; Stevenson MM; Rizzieri DA; Delwel R; Buske C; Bohlander SK; Potti A; Löwenberg B
J Clin Oncol; 2009 Nov; 27(33):5580-6. PubMed ID: 19858393
[TBL] [Abstract][Full Text] [Related]
8. Different clinical importance of FLT3 internal tandem duplications in AML according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathway.
Koh Y; Park J; Ahn KS; Kim I; Bang SM; Lee JH; Yoon SS; Soon Lee D; Yiul Lee Y; Park S; Kim BK
Ann Hematol; 2009 Nov; 88(11):1089-97. PubMed ID: 19296110
[TBL] [Abstract][Full Text] [Related]
9. Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older.
Gardin C; Chevret S; Pautas C; Turlure P; Raffoux E; Thomas X; Quesnel B; de Revel T; de Botton S; Gachard N; Renneville A; Boissel N; Preudhomme C; Terré C; Fenaux P; Bordessoule D; Celli-Lebras K; Castaigne S; Dombret H
J Clin Oncol; 2013 Jan; 31(3):321-7. PubMed ID: 23248249
[TBL] [Abstract][Full Text] [Related]
10. Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients.
Breccia M; Frustaci AM; Cannella L; Stefanizzi C; Latagliata R; Cartoni C; Diverio D; Guarini A; Nanni M; Rago A; Cimino G; Alimena G
Hematol Oncol; 2009 Sep; 27(3):148-53. PubMed ID: 19274612
[TBL] [Abstract][Full Text] [Related]
11. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
Liu J; Mi Y; Fu M; Yu W; Wang Y; Lin D; Bian S; Wang J
Am J Hematol; 2009 Jul; 84(7):422-7. PubMed ID: 19484734
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
Marcucci G; Stock W; Dai G; Klisovic RB; Liu S; Klisovic MI; Blum W; Kefauver C; Sher DA; Green M; Moran M; Maharry K; Novick S; Bloomfield CD; Zwiebel JA; Larson RA; Grever MR; Chan KK; Byrd JC
J Clin Oncol; 2005 May; 23(15):3404-11. PubMed ID: 15824414
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype.
Konoplev S; Rassidakis GZ; Estey E; Kantarjian H; Liakou CI; Huang X; Xiao L; Andreeff M; Konopleva M; Medeiros LJ
Cancer; 2007 Mar; 109(6):1152-6. PubMed ID: 17315232
[TBL] [Abstract][Full Text] [Related]
14. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group.
Tsukimoto I; Tawa A; Horibe K; Tabuchi K; Kigasawa H; Tsuchida M; Yabe H; Nakayama H; Kudo K; Kobayashi R; Hamamoto K; Imaizumi M; Morimoto A; Tsuchiya S; Hanada R
J Clin Oncol; 2009 Aug; 27(24):4007-13. PubMed ID: 19620491
[TBL] [Abstract][Full Text] [Related]
15. Treatment of older patients with AML.
Büchner T; Berdel WE; Wörmann B; Schoch C; Haferlach T; Schnittger S; Kern W; Aul C; Lengfelder E; Schumacher A; Reichle A; Staib P; Balleisen L; Eimermacher H; Grüneisen A; Rasche H; Sauerland MC; Heinecke A; Mesters RM; Serve HL; Kienast J; Hiddemann W
Crit Rev Oncol Hematol; 2005 Nov; 56(2):247-59. PubMed ID: 16246568
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.
Roboz GJ; Ritchie EK; Curcio T; Provenzano J; Carlin R; Samuel M; Wittenberg B; Mazumdar M; Christos PJ; Mathew S; Allen-Bard S; Feldman EJ
Cancer; 2008 Nov; 113(9):2504-11. PubMed ID: 18825661
[TBL] [Abstract][Full Text] [Related]
17. Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500).
Petersdorf SH; Rankin C; Head DR; Terebelo HR; Willman CL; Balcerzak SP; Karnad AB; Dakhil SR; Appelbaum FR
Am J Hematol; 2007 Dec; 82(12):1056-62. PubMed ID: 17696203
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
[TBL] [Abstract][Full Text] [Related]
19. Flt3 internal tandem duplication and P-glycoprotein functionality in 171 patients with acute myeloid leukemia.
Marzac C; Teyssandier I; Calendini O; Perrot JY; Faussat AM; Tang R; Casadevall N; Marie JP; Legrand O
Clin Cancer Res; 2006 Dec; 12(23):7018-24. PubMed ID: 17145823
[TBL] [Abstract][Full Text] [Related]
20. Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup.
Büchner T; Schlenk RF; Schaich M; Döhner K; Krahl R; Krauter J; Heil G; Krug U; Sauerland MC; Heinecke A; Späth D; Kramer M; Scholl S; Berdel WE; Hiddemann W; Hoelzer D; Hehlmann R; Hasford J; Hoffmann VS; Döhner H; Ehninger G; Ganser A; Niederwieser DW; Pfirrmann M
J Clin Oncol; 2012 Oct; 30(29):3604-10. PubMed ID: 22965967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]